Minapharm Pharmaceuticals

The Global Biotechnology Contract Manufacturing Market is projected to grow from USD 15.38 Bn in 2022 to USD 30.87 Bn by 2031, driven by factors like access to expensive technologies, increased flexibility, and speedy product introductions. Key players include Lonza, Samsung Biologics, Thermo Fisher Scientific, and others. The market faces challenges like labeling and packaging issues. The Asia Pacific region shows significant growth potential due to rising R&D investments and healthcare infrastructure improvements.

The Biotechnology Contract Manufacturing Market is projected to grow from $16.28 Bn in 2023 to $31.05 Bn by 2031, driven by increasing demand for biopharmaceuticals, rising R&D investments, and advancements in bioprocessing technologies. Key drivers include the use of biologics in various therapeutic areas and the demand for personalized medicine. Challenges include high manufacturing costs, regulatory compliance, and intellectual property risks. Prominent players include Lonza, Samsung Biologics, and Thermo Fisher Scientific.